Recombinant Mouse SMARCA4 Protein, His (Fc)-Avi-tagged

• Cat.No.: SMARCA4-8461M
• Product Overview: Recombinant Mouse SMARCA4 with His (Fc)-Avi tag was expressed and purified

Specification

• Source: HEK293
• Species: Mouse
• Tag: His&Fc&Avi
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: ≥85% by SDS-PAGE
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Smarca4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 [ Mus musculus ]
• Official Symbol: SMARCA4
• Gene ID: 20586
• mRNA Refseq: NM_001174078.1
• Protein Refseq: NP_001167549.1
• UniProt ID: Q3TKT4

Reviews

02/18/2023

The SMARCA4 protein offers exceptional quality that meets the rigorous demands of experimental research.

11/01/2018

It exhibits exceptional performance in ELISA assays, making it an excellent choice for researchers studying angiopoietins, angiogenesis, or vascular biology.

10/30/2016

Its purity, consistency, and reliable performance make it a top choice for a wide range of applications.

Q&As

Can epigenetic therapies target SMARCA4 alterations?

Epigenetic therapies that modulate gene expression could indirectly affect SMARCA4-altered cancers, though specific targeting remains a challenge.

Are there diagnostic tests for SMARCA4 mutations?

Yes, there are genetic tests available to identify SMARCA4 mutations in tumors, aiding in prognosis and treatment decisions.

Are there ongoing clinical trials focusing on SMARCA4 alterations?

Yes, there are clinical trials exploring new treatment strategies for SMARCA4-altered cancers, aiming to improve patient outcomes.

Is SMARCA4 solely associated with cancer?

No, SMARCA4's functions extend beyond cancer and have implications in various biological processes, including development and differentiation.

How can SMARCA4 mutations influence patient prognosis?

Patients with SMARCA4 mutations in their tumors often face a poorer prognosis, which necessitates tailored treatment approaches.